Caris Life Sciences, Inc. insider trading

Every open-market purchase and sale by Caris Life Sciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $2.4M 6 trades by 5 insiders 3 months later: median +19.6% (+7.6% vs S&P 500) Insider sales, 5 years $28.9M 5 trades by 4 insiders 3 months later: median −33.3% (−30.3% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Caris Life Sciences, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Caris Life Sciences, Inc.’s insiders pay?

From November 10, 2025 to September 23, 2026, 5 insiders reported 3 open-market purchases and 3 sales not made under a pre-set plan in Caris Life Sciences, Inc. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 11, 2025 into $12,758 by November 2, 2026, +28.6% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $11,195 (+12.4% a year), and held throughout $11,195 (+12.4%).

Copying Caris Life Sciences, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Caris Life Sciences, Inc.'s insiders from November 11, 2025, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

Caris Life Sciences, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Denton John Russel	See Remarks	1	—	—	1	—	September 23, 2026
Brille Brian J	See Remarks	0	—	—	1	—	September 17, 2026
Halbert Jon	Director	1	—	—	0	—	July 13, 2026
Spetzler David Baxley	President	0	—	—	1	—	September 4, 2026
Vacirca Jeff L	Director	1	—	—	0	—	May 12, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Caris Life Sciences, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Caris Life Sciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
September 30, 2026	3 selling	not yet	not yet	not yet
July 31, 2026	2 buying	+127.4%	not yet	not yet

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Caris Life Sciences, Inc. · Funds · Politicians